SCHEMBL29759759

SCHEMBL29759759

Cc1ncc(NC(=O)CN2CCO[C@H](C)C2)cc1NC(=O)c1cnn2cc(-c3cnn(C)c3)sc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 9/20 0.49
▸ DYRK1A Q13627 8/20 0.49
▸ WNT1 P04628 7/20 0.49
▸ CCNC P24863 1/20 0.38
▸ CDK8 P49336 1/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ PDGFRA P16234 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.38
▸ GRM2 Q14416 3/20 0.35
▸ CSF1R P07333 1/20 0.35
▸ KIT P10721 1/20 0.35
▸ GSK3A P49840 4/20 0.34
▸ MAPT P10636 3/20 0.33
▸ PIM1 P11309 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ CDK5 Q00535 1/20 0.33
▸ PRKCQ Q04759 1/20 0.33
▸ AAK1 Q2M2I8 1/20 0.33
▸ CLK2 P49760 1/20 0.33
▸ LRRK2 Q5S007 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29759990 1.00 GSK3B (0.49) GSK3BDYRK1AWNT1CCNCCDK8
SCHEMBL24578483 1.00 GSK3B (0.49) GSK3BDYRK1AWNT1CCNCCDK8
SCHEMBL27184987 1.00 GSK3B (0.49) GSK3BDYRK1AWNT1CCNCCDK8
SCHEMBL27185310 1.00 GSK3B (0.49) GSK3BDYRK1AWNT1CCNCCDK8
SCHEMBL30566456 0.92 GSK3B (0.40) GSK3BDYRK1AWNT1CHRM1PDGFRA
SCHEMBL29759780 0.92 GSK3B (0.40) GSK3BDYRK1AWNT1CHRM1PDGFRA
SCHEMBL29759981 0.92 GSK3B (0.40) GSK3BDYRK1AWNT1CHRM1PDGFRA
SCHEMBL29759672 0.91 GSK3B (0.46) GSK3BDYRK1AWNT1CHRM1PDGFRA
SCHEMBL29759655 0.91 GSK3B (0.46) GSK3BDYRK1AWNT1CHRM1PDGFRA
SCHEMBL29759842 0.90 GSK3B (0.45) GSK3BDYRK1AWNT1CHRM1PDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2024-04-04 — — US disclosed
EP-4267585-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS Actelion Pharmaceuticals Ltd (CH) 2023-11-01 — — EP disclosed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS PDGFRA, PDGFRB, ABL1 GSK3B 1914/4885DYRK1A 1429/4885WNT1 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback